8-K current report · filed Jul 6, 2026

Nuvation Bio Inc. (NUVB) 8-K Current Report: July 6, 2026

Item 1.01Item EX-99.1Item 2.03Item 8.01NUVB overview

Short answer

Nuvation Bio Inc. (NUVB) filed an 8-K current report with the SEC on July 6, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item EX-99.1 (Exhibit EX-99.1), Item 2.03 (Creation of a Direct Financial Obligation), Item 8.01 (Other Events). Additional capped calls executed July 1, 2026, tied to the Greenshoe Exercise.

Nuvation Bio Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • Additional capped calls executed July 1, 2026, tied to the Greenshoe Exercise
  • Designed to reduce potential Class A common-stock dilution upon convertible-note conversion
  • Potential offset for cash payments exceeding converted-note principal
  • Initial $10.4580 cap price, representing an 80.0% premium to June 25 NYSE closing price

Item 2.03 · Creation of a Direct Financial Obligation

  • $287.5M convertible notes issued, including $37.5M greenshoe exercise, expanding long-term financing
  • 0.75% annual interest, $1.00B? 2032 maturity?
  • Approximately $277.6M net proceeds, with $2.2M funding additional capped calls
  • Remaining proceeds for working capital, operating expenses, capital expenditures and general corporate purposes
  • Capped calls, cap price initially $10.4580 per share, expected to reduce conversion dilution up to the cap

Item 8.01 · Other Events

  • July 6, 2026 press release announces additional convertible Notes issued through the Greenshoe Exercise
  • Additional capped call confirmations entered, potentially reducing future equity dilution from note conversions
  • Investors should review Exhibit 99.1 for offering size, proceeds, conversion terms and capped call details

Item EX-99.1 · Exhibit EX-99.1

  • Greenshoe fully exercised, increasing convertible notes offering to $287.5 million
  • Notes carry 0.75% interest and mature in 2032, adding low-cost long-term financing
  • Estimated net proceeds approximately $277.6 million after underwriting discounts and offering expenses
  • Additional capped calls cost approximately $2.2 million, with an $10.4580 cap price
  • Remaining proceeds earmarked for working capital, operating expenses, capital expenditures and general corporate purposes

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Nuvation Bio Inc. 8-K filings

Get the next NUVB 8-K as it lands

Follow NUVB for push alerts, or ask the research agent what this filing means.